Diabetes Medication, Amputation Risk, and the Invokana Lawsuits
If you take a diabetes medication like Invokana and you have seen the word amputation in a lawsuit ad, that is a frightening thing to sit with. The fear is understandable, and the real story is more reassuring and more complicated than the ads suggest.
This guide explains what the research actually found, how the FDA warning changed, and where the lawsuits stand today, in plain terms.
One diabetes drug, canagliflozin, was linked to roughly double the amputation risk in 2017, but newer data led the FDA to remove that warning in 2020, and the wave of lawsuits has largely closed. Understanding that timeline matters more than any headline.
This Article Is Not Medical or Legal Advice
This guide is general educational information for amputees and their families. It is not medical or legal advice and does not create a doctor-patient or attorney-client relationship. Never start, stop, or change a prescription medication without talking to your care team. Drug safety information and litigation status change over time, so consult your doctor about the medical questions and a licensed attorney in your state about the legal ones.
What You Will Learn in This Article
- What SGLT2 diabetes medications are and why one of them raised an amputation concern.
- How the FDA added a boxed amputation warning in 2017 and then removed it in 2020.
- Where the diabetes medication amputation lawsuits stand today, and what that means for you.
What SGLT2 Diabetes Medications Are and How They Work
SGLT2 inhibitors treat type 2 diabetes by making the kidneys flush extra sugar out in the urine, and the amputation concern centered on just one of them.
SGLT2 inhibitors are a class of type 2 diabetes drugs that lower blood sugar in an unusual way. They block a protein in the kidneys called SGLT2, so your body passes excess glucose out in the urine instead of holding onto it.
The class includes canagliflozin, sold as Invokana, along with dapagliflozin, sold as Farxiga, and empagliflozin, sold as Jardiance. These drugs are now widely used because they also protect the heart and kidneys.
The amputation concern that drove the lawsuits was tied specifically to canagliflozin, not to the whole class. That distinction is at the center of everything that followed.
The Amputation Risk That Triggered the Warning
Two large 2017 trials found canagliflozin roughly doubled the rate of leg and foot amputations, most often at the toe or midfoot.
The alarm came from real evidence, not speculation. A large clinical trial program tracking heart outcomes found a clear and unexpected signal for amputations.
In the CANVAS program, leg and foot amputations occurred about twice as often in people taking canagliflozin as in those taking a placebo, roughly 6.3 versus 3.4 per 1,000 patient-years. Most were at the level of the toe or midfoot.
Because most of these were toe and forefoot amputations, the injuries sat at the milder end of the limb-loss spectrum, though no amputation is minor to the person living it. Our guide to toe amputation covers what recovery at that level involves.
On the strength of that 2017 data, the FDA required canagliflozin to carry a boxed warning, its most serious type of label warning, for lower limb amputation.
How the FDA Warning Changed Over Time
After reviewing newer trial data, the FDA removed the boxed warning in 2020, finding the risk lower than first described, though it is still listed on the label.
The 2017 warning was not the end of the story. As more data came in from later trials, the picture changed in an important way.
The Canagliflozin Amputation Warning Timeline
Two large trials link canagliflozin to roughly double the amputation rate, and the FDA adds a boxed warning.
After reviewing newer data, the FDA removes the boxed warning, finding the risk lower than first described and outweighed by heart and kidney benefits.
The federal Invokana lawsuits close, with most earlier cases already resolved and few new ones filed.
On August 26, 2020, the FDA removed the boxed amputation warning from canagliflozin, citing newer trials that showed the risk was lower than first described, especially with proper monitoring. The benefit to the heart and kidneys had also become clearer.
The risk did not vanish. It is still described in the warnings and precautions section of the label, just no longer in the most severe boxed format.
Where the Lawsuits Stand Today
The Invokana amputation lawsuits were consolidated in a federal court, largely resolved through private settlements, and the litigation closed in 2023.
After the 2017 warning, thousands of people who had amputations while taking Invokana filed claims. Because these were claims that a product caused harm, they followed the same product liability path our guide to a defective product amputation claim describes.
The federal cases were grouped into a single proceeding in New Jersey, and the manufacturer resolved most of them through private settlements whose terms were not disclosed. That federal litigation closed in 2023, and drug-injury trackers report that few if any attorneys are still accepting new Invokana amputation cases.
This is the part the lawsuit ads rarely mention. The window for these specific claims has largely closed, in part because the filing deadlines set by each state's statute of limitations for an amputation injury have passed for most people.
What This Means If You Take or Took One of These Drugs
Do not stop your medication on your own, talk to your care team about foot monitoring, and if you had an amputation, a lawyer can still tell you whether any claim remains.
If you are taking one of these drugs right now, the single most important step is simple. Do not stop it on your own, because the heart and kidney benefits are real and stopping suddenly can be dangerous.
Talk to your care team about your own risk, especially if you have foot ulcers, neuropathy, or a prior amputation, and ask what foot monitoring makes sense for you. That conversation matters far more than any lawsuit.
If you already had an amputation while taking Invokana, a personal injury attorney can tell you for free whether any claim remains open in your situation, and what categories of amputation injury compensation could apply. A directory of vetted attorneys is on our amputation injury lawyer hub.
What This Guide Cannot Tell You
This is general background on the drugs and the litigation, not medical advice about your treatment or a judgment about your specific claim.
The facts here describe the research, the FDA actions, and the litigation as of June 2026, and all three can change. Whether a drug is right for you is a medical decision, and whether you have a viable claim is a legal one, each needing a professional who knows your situation.
An Honest Note
Lawsuit ads often make a closed or narrow situation sound urgent and open. The honest picture is that canagliflozin's amputation risk was real but smaller than first feared, the FDA softened its warning in 2020, and the litigation has largely ended. Your doctor is the right person for the medical question, and an attorney can confirm the legal one without charging for the conversation.
Closing thoughts
The diabetes drug amputation story is a real risk that turned out smaller than feared, so the steady work of diabetes foot care matters more now than the old lawsuits.
The amputation concern with canagliflozin was genuine, and the people it affected deserved answers. But the science settled into a calmer place, and the FDA followed the evidence in both directions.
For almost everyone reading this today, the useful action is not legal. It is steady blood sugar control, regular foot checks, and an honest conversation with your care team about your own risk.
If an amputation has already changed your life, the next step is a free conversation with a lawyer who can tell you plainly whether any claim remains.
Frequently Asked Questions
The amputation concern centered on canagliflozin, sold as Invokana, Invokamet, and Invokamet XR. It is an SGLT2 inhibitor, a class that also includes dapagliflozin (Farxiga) and empagliflozin (Jardiance), but the strong amputation signal in the 2017 trials was specific to canagliflozin.
The FDA removed canagliflozin's boxed amputation warning in 2020 after newer data showed the risk was lower than first described, especially with proper monitoring. The risk is still listed in the warnings and precautions section of the label, so people with foot ulcers, neuropathy, or a prior amputation should discuss it with their care team.
For most people, no. The federal Invokana litigation closed in 2023, most earlier cases were settled privately, and few if any attorneys are accepting new cases. Because each state's filing deadline has passed for most claimants, the window has largely closed, but a lawyer can tell you for free whether anything remains in your specific situation.
Not on your own. These drugs have real heart and kidney benefits, and stopping suddenly can be dangerous. Talk to your care team about your personal risk and what foot monitoring makes sense before making any change.
The biggest protections are steady blood sugar control, daily foot checks, well-fitting shoes, and prompt care for any sore or wound that does not heal. Regular visits with your care team to catch problems early matter far more than any single medication decision.
Last updated June 2026. Drug safety data, FDA labeling, and litigation status change over time. Confirm current medical guidance with your care team and current legal options with a licensed attorney before relying on anything here.